Thomas C, Chung J, Landsburg D, Nasta SD, Svoboda J, Chong E, Schuster S, Carter J, Cook M, Tomasulo E, Elghway O, Lariviere M, Hubbeling H, Plastaras J, Villasenor-Park J, Myers C, Ruella M, Rook A, Kim E, Barta S. Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden. , In Proceedings of 67th American Society of Hematology Annual Meeting 2025: 2025
Knoedler L, Herfeld K, Schaefer DA, Diatta F, Clune J, Evans B, Seu M, Kim BS, Alfertshofer M, Schaschinger T, Iske J, Knoedler S, Lellouch AG, Jeljeli M, Carturan A, Ruella M, Heiland M, Poeck H, Perl M, Pomahac B, Kauke-Navarro M. CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review. , Cell Rep Med, 6(8): 2025
Porazzi P, Pucillo M, Anant Padmanabhan A, Nason S, Zheng Z, Paruzzo L, Ho M, Michener P, Stella F, Imparato A, Susanibar-Adaniya S, Garfall A, Fraietta J, Ruella M. Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma. , In Proceedings of 67th American Society of Hematology Annual Meeting: 2025
Svoboda J, Schuster S, Porter D, Cook M, Nasta SD, Landsburg D, Barta S, Ruella M, Chong E, Carter J, Thomas C, Tomasulo E, Frey N, Connor M, Shea J, Cervini A, McConville J, Tongue C, Four M, Marshall A, Hwang WT, Leskowitz R, Gonzalez V, Christensen S, Plesa G, Siegel D, Jadlowsky J, Fraietta J, Levine B, Hexner E, June C. IL18-armored CAR T cells in patients with CLL/SLL and Richter’s transformation after prior BTK inhibitor and venetoclax failure. , In Proceedings of 67th American Society of Hematology Annual Meeting: 2025
Precision targeting of immune-mediated thrombotic thrombocytopenic purpura (iTTP) with chimeric auto-antigen receptor (CAAR) T cells. Khadka R, Cohen I, Parvathaneni K, Lemoine J, Jung S, Bochi-Layec A, Zhao H, Hresko M, Siegel D, Ruella M, Bhoj V. , In Proceedings of 67th American Society of Hematology Annual Meeting: 2025
Han Noll J, Ho M, Paruzzo L, Stella F, Devi P, Ndeupen S, Chen G, Cohen I, Ramierz-Fernandez A, Waxman A, Kapur S, Chen F, Xu R, Huff A, Jarocha D, Patel V, Bochi-Layec A, Ramasubramanian R, Liu S, Bouvier R, Souza V, Patel H, Li Z, Carturan A, Michener P, Hopkins C, Koucky O, Minehart J, Dimitri A, Nabar N, Hasanali Z, Ciccarelli B, Williams E, Bartoszek R, Lavorando M, Mohan S, Gonzalez V, Porazzi P, Bhoj V, Apostolidis S, Vogl D, Porter D, Scholler J, Diorio C, Doto A, Everett J, Bushman F, Nathanson K, Stadtmauer E, Susanibar-Adaniya S, Garfall A, Ruella M, Cohen A, Fraietta J. Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells. , In Proceedings of 67th American Society of Hematology Annual Meeting 2025: 2025
Cohen A, Susaniber-Adaniya S, Garfall A, Vogl D, Kapur S, Waxman A, Zubka D, Hwang WT, Diaczynsky C, Han Noll J, Ho M, Paruzzo L, Bing Y, Xu R, Thai E, Gonzalez V, Michener P, Ruella M, Fraietta J, Stadtmauer E. Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial. , In Proceedings of 67th American Society of Hematology Annual Meeting 2025: 2025
Stella F, Schneider M, Paruzzo L, Han Noll J, Devi P, Babatunde V, Chong E, Ho M, Thomas C, Cook M, Hossain N, Carter J, Li Z, Tan M, Michener P, Guruprasad P, Patel V, Imparato A, Carturan A, Lemoine J, Souza V, Porazzi P, Fraietta J, Barta S, Nasta SD, Svoboda J, Schuster SJ, Maillard I, Landsburg D, Ruella M. Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells. , In Proceedings of 67th American Society of Hematology Annual Meeting: 2025
Lemoine J, Cohen I, Croston G, Bochi-Layec A, Espie D, Ramasubramanian R, Porazzi P, Stella F, Bayat P, Jung S, Iatrou Anastasia, Agathangelidis A, Schuster S, Ghia P, Stamatopoulos K, Ruella M. Precision targeting of the malignant clone in B-cell malignancies using chimeric antigen receptor T cells against the clonotypic IGHV3-23 B cell receptor. , In Proceedings of 67th American Society of Hematology Annual Meeting: 2025
Cohen I, Khadka R, Lemoine L, Bochi-Layec A, Jung S, Kim KH, Zhao H, Hresko M, Siegel D, Ghia P, Stamatopoulos K, Schuster S, Bhoj V, Ruella M. Precision targeting of autoantibody-producing IGHV1-69+ B cells in immune-mediated thrombotic thrombocytopenic purpura (iTTP) using chimeric antigen receptor T cells. , In Proceedings of 67th American Society of Hematology Annual Meeting 2025: 2025
